Genome– tag –
-
Broad Institute Achieves Major Breakthrough in Prime Editing: Enhanced In Vivo Delivery with Optimized LNPs Paves Way for Broader Genetic Disease Therapies
Broad Institute USA Overview Researchers at the Broad Institute have significantly improved the efficiency and specificity of prime editing by optimizing its core components and developing an advanced lipid nanoparticle (LNP) delivery sy... -
Non-Viral CRISPR/Cas9 HDR Platform Enables Stable Genetic Engineering of Solid Tumor Models, Overcoming Viral Vector Challenges
bioRxiv (Preprint) USA Overview This preprint reports research on a non-viral CRISPR/Cas9 Homology-Directed Repair (HDR) platform for stable genetic engineering of solid tumor models. This approach enables precise genome modification and... -
REPROCELL Develops Hypoimmune iPSC Engineering with AI-Designed CRISPR for Off-the-Shelf Cell Therapies
REPROCELL Japan Overview REPROCELL announced a method to develop hypoimmune iPSCs using AI-designed CRISPR, leveraging its StemEdit gene-editing platform. This approach targets key immune recognition genes like B2M and CIITA to create un... -
FDA Issues Draft Guidance to Streamline Regulatory Submissions for Cell and Gene Therapy Products by Leveraging Prior Knowledge
Pharmuni USA Overview The U.S. FDA has released new draft guidance aimed at accelerating the development of cell and gene therapy products for rare diseases. This guidance permits developers to leverage existing scientific, manufacturing... -
Caribou Biosciences’ Off-the-Shelf Allogeneic CAR T Vispa-cel Shows Superior PFS to Approved Autologous CAR T Therapies in Lymphoma Phase 1
Fierce Biotech USA Overview Caribou Biosciences announced promising median progression-free survival (PFS) data from its Phase 1 clinical trial of vispacabtagene regedleucel (vispa-cel), an off-the-shelf allogeneic CAR T-cell therapy for... -
CRISPR Gene Editing Evolves with Cas12a2 to Shred Sick Cell DNA, Expanding Therapeutic Horizons for Cancer and Viral Infections
Top Doctor Magazine USA Overview The CRISPR gene editing landscape is rapidly evolving in 2026, driven by the FDA approval of Cas9-based CASGEVY and the discovery of the novel Cas12a2 protein's ability to 'shred' diseased cell DNA. Unlik... -
Precision BioSciences Unveils Promising Preclinical Data for In Vivo Gene Editing Therapy in Duchenne Muscular Dystrophy
Morningstar USA Overview Precision BioSciences has presented encouraging preclinical data for PBGENE-DMD, an in vivo gene editing therapy targeting Duchenne Muscular Dystrophy, at the 2026 ASGCT Annual Meeting. Early intervention in youn...
